Family-based studies identified specific mutations in APOB and PCSK9 as etiological factors contributing to development of familial hypercholesterolemia by either impeding the binding of LDL particles to the receptors, thus hindering the uptake, or by enhancing the catabolism of LDL receptors [3]. The gene discussed is LDLR; the disease is familial hypercholesterolemia.